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Abstract 
Imaging genetics deals with relationships between genetic variation and imaging variables, often in a disease context. 
The complex relationships between brain volumes and genetic variants have been explored with both dimension 
reduction methods and model-based approaches. However, these models usually do not make use of the extensive 
knowledge of the spatio-anatomical patterns of gene activity. We present a method for integrating genetic markers 
(single nucleotide polymorphisms) and imaging features, which is based on a causal model and, at the same time, 
uses the power of dimension reduction. We use structural equation models to find latent variables that explain brain 
volume changes in a disease context, and which are in turn affected by genetic variants. We make use of publicly 
available spatial transcriptome data from the Allen Human Brain Atlas to specify the model structure, which reduces 
noise and improves interpretability. The model is tested in a simulation setting and applied on a case study of the 
Alzheimer’s Disease Neuroimaging Initiative.
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1 Introduction
The aim of imaging genetics studies is to find associations 
between genetic variants and imaging features, often in 
a disease context [1]. This scheme extends beyond tra-
ditional genome-wide association studies (GWAS) by 
identifying genetic associations of imaging biomarkers 
with the assumption that these biomarkers are a more 
direct reflection of the genetic effects. Thus, they could 
provide a stronger association signal [2]. Additionally, the 
identified associations are likely to provide new insights 
into the underlying disease mechanisms as well as new 
hypotheses about the anatomical and/or functional loca-
tions involved in complex diseases [3].
So far, imaging genetics studies have been largely 
focused on the brain [1, 3–6], despite efforts to extend 
their application to other fields [7]. Several large con-
sortia have gathered data from thousands of subjects 
to understand the effects of genetic variants on brain 
structure and function [8]. One of the hallmark sources 
for imaging genetics studies is the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database [9]. This data-
base contains single nucleotide polymorphism (SNP) and 
structural MRI data for Alzheimer’s patients, individuals 
with late mild cognitive impairment, and cognitive nor-
mal controls.
One of the largest challenges facing imaging genetics 
studies is the statistical power needed to identify reliable 
associations. In a typical GWAS, researchers have to cor-
rect for the number of independent tests performed (i.e. 
number of independent SNPs tested) in order to limit the 
number of false-positive discoveries. However, a genome-
wide brain-wide imaging genetic study will not only have 
to correct for the number of independent SNPs, but also 
for the number of independent imaging features tested. 
As a result, many studies are underpowered to identify 
reliable associations. One of the largest imaging genetics 
studies [10] analysed over 30,000 individuals within the 
Enhancing Neuro Imaging Genetics through Meta-Anal-
ysis (ENIGMA) consortium. They performed a genome-
wide association of SNPs with seven brain volumes and 
identified only eight genome-wide significant SNPs.
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Despite the high dimensionality of the imaging data 
(millions of voxels), the actual number of independent 
tests for which we need to correct in an imaging genet-
ics study is far smaller than the number of voxels. Due to 
the spatial relationships between voxels, measurements 
from neighbouring voxels are usually highly correlated. 
A common approach is to test genetic associations for 
anatomically defined brain regions [2]. Several studies 
have shown that both neuroanatomical parcellation and 
connectivity of the brain are strongly reflected in gene 
expression patterns across the brain [11–13]. The public 
availability of brain transcriptome atlases from the Allen 
Institute for Brain Science [14] provides an opportu-
nity to use these transcriptional signatures to group  the 
anatomically defined brain regions, further  limiting the 
number of effective tests.
Several methods have been proposed to identify asso-
ciations between genetic variants and imaging features 
by applying dimension reduction, such as variations of 
canonical correlation analysis [15], and independent 
component analysis (commonly used in a functional MRI 
context) [4]. Others have opted to model the interactions 
between the different data types explicitly, for instance 
using graphical Bayesian models [16, 17] which capture 
a more mechanistic causal view of the data. These mod-
els consist of a directed acyclic graph, which can easily 
be made to incorporate covariates, including possible 
confounding factors. Both of these studies use relatively 
small candidate SNP sets, because they aim for under-
standing SNP–brain relationships rather than the dis-
covery of genome-wide associations. However, these 
Bayesian models are quite challenging to specify and fit.
In this work, we propose a method to identify asso-
ciations between candidate genetic variants and imaging 
features allowing for the incorporation of prior knowl-
edge. The proposed method combines a graphical model 
with dimension reduction to model the effect of SNPs 
on brain imaging features through a set of latent varia-
bles. We use a maximum likelihood structural equation 
modelling (SEM) approach to find the edge weights of 
our model [18]. By performing dimensionality reduc-
tion within the model, we reduce the number of param-
eters to be estimated. In addition, the model allows for 
easy incorporation of information from the Allen Human 
Brain Atlas [12] to inform the grouping of brain regions 
based on the similarity of their transcriptional profiles.
Our model uses the transcriptional profiles for group-
ing because we consider gene expression to be an inter-
mediate phenotype, that links SNPs to brain imaging 
features. Most disease-associated SNPs are located near 
regulatory regions of the genome [19], and the effects of 
SNPs on expression tend to be tissue and cell type spe-
cific [20]. Gene expression data of brain regions reflect 
cell type composition and anatomical similarity [12] and 
capture a wide range of brain-specific molecular path-
ways [21]. For these reasons the region groups in the 
dimension reduction are based on spatial gene expres-
sion data of the brain.
2  Materials and methods
The interplay between genetic variation, brain anatomy, 
and disease symptoms is complex. We use a structural 
equation model with latent variables [18] to model 
these relationships. We pose that the genetic variation 
is exogenous; in other words, the genetic variation in a 
study population is not caused by disease or brain anat-
omy. This variation does have an effect on the brain. For 
example, in Alzheimer’s disease, genetic variants may 
influence the immune response and amyloid β concentra-
tions in the brain, which may in turn lead to shrinkage in 
several brain areas [22]. Large-scale imaging initiatives, 
such as ADNI, offer a possibility to study this shrinkage 
of brain regions. This can be estimated from MRI data of 
diseased individuals and controls, and expressed in corti-
cal thickness and subcortical volume measurements.
In our graphical model, we define groups of brain 
regions, based on the transcriptional profiles of these 
areas in the healthy brain. Areas that share patterns 
of gene expression in a normal brain may be similarly 
affected by genetic variations. For each of the region 
groups, we introduce one latent variable. This latent 
variable is affected by the genetic variations and causes 
changes in relevant brain regions. This makes our model 
similar to principal component analysis (PCA) on sets of 
brain regions, combined with a regression for the latent 
variables. However, in our model the weights are esti-
mated together, and the latent variables reflect not only 
the correlations between the regions (as in a conventional 
PCA), but also those between regions and SNPs and 
among the SNPs.
2.1  Variables used
We model the relationship between single nucleotide pol-
ymorphisms (SNPs) and brain region measurements. Let 
gi ∈ R
p be a vector of centred (zero-mean) SNP values, 
and xi ∈ Rq a vector of centred (zero-mean) and scaled 
( sd = 1 ) brain region measurements, both for individual 
i. The reason both types of measurements are centred is 
to eliminate intercepts from the model. The brain meas-
urements are, in addition, scaled to unit variance to com-
pensate for the considerably larger variance in thickness 
or volume for larger brain areas. The genetic variants and 
brain measurements are connected in the model by a set 
of latent variables, zi ∈ Rm.
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In addition to the variables included in the model, we 
have two other sources of information. In defining the 
model structure, we make use of external information 
on the brain region measurements, in the form of brain 
region groups with a shared transcriptional profile. These 
groups are defined based on the  spatial gene expres-
sion data of the healthy adult brain. Finally, the goal is 
to understand disease-related phenotypes. The disease 
labels are not used in the modelling stage. However, we 
hypothesize that if the variation in the data is related to 
a disease state, the latent variables will reflect this. After 
model fitting, we therefore associate each individual’s 
estimated latent variable score with his or her disease 
status.
2.2  The graphical model
We model the relationship between brain SNP values 
and brain region measurements in a structural equation 
model (SEM). It consists of two parts. The first part is a 
linear model for brain region measurements as a function 
of the latent variables,
where xi contains the observed brain region measure-
ments, zi are the latent variables, and ζ i is a zero-mean 
normally distributed error variable. The matrix B con-
tains the weights of the latent variables that explain the 
brain region measurements. The second part of the SEM 
is a linear model for these latent variables as a function of 
the SNP values,
where gi contains the observed SNP measurements and 
εi is a zero-mean normally distributed error variable. The 
matrix A contains regression weights, representing the 
effects of the SNPs on the latent variables. Combined, 
these equations mean that region changes are viewed as 
a manifestation of the latent values, while the SNP values 
are considered causal to them. The latent variables repre-
sent some intermediate phenotype, related to the molec-
ular state of the connected brain regions.
The number of latent variables is equal to the number 
of brain region groups, which are defined based on exter-
nal spatial gene expression data. A region group contains 
the brain regions with a similar transcriptional profile, as 
these may react similarly to differences in genetic back-
ground. We restrict each latent variable to only predict 
the brain region measurements for its own region group. 
This results in a restriction on the weight matrix B , where 
each latent variable (corresponding to a column in B ) has 
a unique set of nonzero entries. Figure 1 shows the model 
for two latent variables, where we can see that each latent 
variable is connected to its own set of brain regions.
(1)xi = Bzi + ζ i,
(2)zi = Agi + εi,
2.3  Model implied covariance
In linear Gaussian structural equation modelling, we learn 
the parameters of a model by optimizing the correspond-
ence between the observed covariance S (from the data) 
and the model implied covariance Σ . The model implied 
covariance can be divided into a block matrix, by defining
Note that this implied covariance does not contain any 
components for the latent variables in z . The latent vari-
ables are not observed, and therefore, we cannot use their 
observed covariance in fitting the model.
The elements of the implied covariance can be parame-
terized in terms of the model coefficients. The first element 
is
This is the covariance of the SNPs (since these values are 
centred). The SNPs are exogenous in our model: g does 
not have any causal variables within our model. As a 
result, the implied covariance of the SNPs is not param-
eterized in terms of model coefficients. We can esti-
mate this covariance term simply by taking the observed 
covariance between the SNPs.






































Fig. 1 The graphical structural equation model. Observed variables 
are shown in grey circles, latent variables in white circles, and error 
variables without circles. This example contains two latent variables, 
both with their own set of observed brain region measurements. 
This structure, where the latent variables define groups of region 
measurements, is defined by prior knowledge on these brain regions. 
We use spatially resolved gene expression data of the healthy human 
brain to define these region groups
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and similarly
The final element of the implied covariance matrix is the 
model implied covariance among the brain regions. This 
is given by
2.4  Model assumptions and estimation
Some elements of the implied covariance are often 
assumed to be zero. These assumptions lead to a strong 
simplification of the implied covariance. It is com-
mon in a regression setting to pose that the predic-
tor variables and error variables are independent. In 
our case, the error independence assumption leads to 
gεT = εgT = 0 . In addition, we assume that the errors 
in the brain region predictions (Eq. 1) are independent 
of the errors in the latent variable predictions (Eq.  2). 
This means that ζεT = εζT = 0 . Finally, we assume that 
the errors in brain region prediction are independent of 
the SNPs, so gζT = ζgT = 0.
As a result of these assumptions, the full implied 
covariance matrix of the model reduces to
For normally distributed data, the maximum likelihood 
estimate of the covariance matrix is
where S is the observed covariance matrix. The SNP data 
we use are discrete and can therefore not be considered 
normally distributed. To compensate for this, we will 
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Σ is parameterized according to Eq.  (3), so we can per-
form the optimization over the parameter values.
Model fitting is performed in the lavaan package in R 
[23]. For identifiability, we fix the loading of the first brain 
region measurement per region group (latent variable) to 
1. This does not only fix the scales of the latent variables, 
but it also has the advantage that the resulting latent 
variables will have the same direction of effect as the first 
brain region measurement. For example, a reduction in 
volume of the first brain region will result in a reduction 
in the corresponding latent variable. All the error vari-
ances on the brain region measurements (variance of ζ ) 
are assumed to be equal within each region group, which 
is the same as in principal component analysis.
The model fit in lavaan yields estimates for B , A , and 
the covariance matrices of the error variables ε and 
ζ . Each of these parameter estimates is provided with 
robust p values (for the hypothesis of being equal to 
zero), when using the MLM estimation procedure [23]. 
Using the estimated model parameters, one can then 
calculate unbiased Bartlett scores for the latent variables 
[24].
2.5  Data
Simulated data The model is evaluated on both simulated 
and real data. In the simulation, we first generated SNP 
values ( gi ) in accordance with Hardy–Weinberg equilib-
rium. The minor allele frequencies were independently 
drawn from a beta distribution with shape parameters 
α = 1 and β = 2 . Then we simulated latent variables ( zi ) 
as a linear combination of the SNP values, with Gaussian 
noise ( sd = 2 ). Each of these latent variables determined 
the region measurements ( xi ) of a set of regions (a region 
group), with added Gaussian noise ( sd = 2 ). This part of 
the simulation is in line with Eqs. (1) and (2) and Fig. 1. 
Finally, we used a logistic model in which a linear com-
bination of some of the latent variables determined the 
probability of observing a phenotype. These binary phe-
notypes (disease versus healthy) were then drawn from a 
Bernoulli distribution.
We simulated 100 independent data sets for 500 indi-
viduals. Each time, we set the number of SNPs to 20 
and the number of latent variables (and therefore region 
groups) to 5. We randomly selected 10 SNP-to-latent 
weights ( A ) to be either 1 or − 1 . The 5 region groups 
contain 20, 10, 10, 5, and 5 regions, respectively, for a 
total of 50 brain region measurements. Each latent vari-
able has latent-to-brain-region weights (in B ) which were 
uniformly sampled between 0.5 and 1.5. All other ele-
ments of B were set to zero, which effectively restricts 
each latent variable to affect only its own region group. 
Finally, two out of the five latent variables were randomly 
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selected to affect the disease probability, with weights of 
either 10 or −10 . All other latent-to-phenotype weights 
were set to zero.
To test the robustness of our method, we also simu-
lated data for a range of alternative parameter settings. 
We varied the amount of noise in the latent variables ( zi ) 
and the region measurements ( xi ) between 1 and 5. The 
number of nonzero SNP-to-latent weights (in A ) was var-
ied from 2 to 20. Finally, we constructed data sets with 
misspecified latent-to-brain-region weights (in B ). To 
this end, we swapped links between latent variables and 
regions. In each swap, a region was disconnected from its 
original latent variable and instead connected to another 
latent variable. To retain the sizes of the region groups, 
another region of that second latent variable was then 
connected to the first latent variable. Each swap therefore 
resulted in two misspecified links. We made sure not to 
swap regions back to their original latent variables.
ADNI data and preprocessing The real data used in the 
preparation of this article were obtained from the Alzhei-
mer’s Disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu) [9]. The ADNI was launched in 2003 
as a public–private partnership, led by Principal Investi-
gator Michael W. Weiner, MD. The primary goal of ADNI 
has been to test whether serial magnetic resonance imag-
ing (MRI), positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological 
assessment can be combined to measure the progression 
of mild cognitive impairment (MCI) and early Alzhei-
mer’s disease (AD). For up-to-date information, see www.
adni-info.org.
The ADNI database contains measurements on a large 
number of cognitive normal (CN) controls, individuals 
with late mild cognitive impairment (LMCI), and individ-
uals with Alzheimer’s disease (AD). The measurements in 
the database include patient demographics, raw and pro-
cessed MRI data, biomarker data, and SNP data. For the 
brain volumes we made use of the UCSF cross-sectional 
FreeSurfer (version 4.3) cortical thickness and white mat-
ter parcellation measurements. For the SNPs we made 
use of the ADNI 1 Illumina Human 610-Quad BeadChip 
data, with imputation as previously described [17]. In the 
end, we selected volumes, SNPs, and diagnoses for 746 
individuals. These data were split into two equal parts of 
373 individuals, one as a training set and one as a valida-
tion set, to prevent over-fitting in the modelling process.
Our methodology is not suited to genome-wide analy-
sis. Instead, it tries to find the effects of specific SNPs on 
a set of latent variables. As candidate SNPs we selected 
a set of 35 polymorphisms associated with Alzheimer’s 
disease according to the International Genomics of Alz-
heimer’s Project (IGAP) study results [25]. IGAP is a 
two-stage GWAS on individuals of European ancestry 
for Alzheimer’s disease. In stage 1, IGAP used genotyped 
and imputed data on 7,055,881 SNPs of 17,008 Alzhei-
mer’s disease cases and 37,154 controls. In stage 2, 11,632 
SNPs were genotyped and tested for association in an 
independent set of 8,572 Alzheimer’s disease cases and 
11,312 controls. Finally, a meta-analysis was performed 
combining results from stages 1 and 2. We selected the 
known SNPs, stage 1 discoveries, and stage 1 and stage 
2 discoveries from table 2, and the suggestive SNPs from 
supplemental table 4 of [25].
The volume data were present for 112 regions. We 
corrected it for individual age, gender, and whole brain 
volume (using linear regression), with the goal of main-
taining all meaningful variation in brain region volumes, 
possibly related to the disease phenotype. For our latent 
variable model, the brain region volumes were linked to 
region groups. We defined these region groups based on 
the transcriptional profiles in the healthy adult human 
brain, as provided by the Allen Atlas [12]. This gene 
expression resource contains anatomically labelled meas-
urements taken from six human brains. Regions with 
measurements in each of the six brains were selected, 
and the expression values were averaged to obtain a sin-
gle value for each of the 19,992 genes in each of the 105 
regions of the Allen Atlas [21]. We then performed a 
t-distributed neighbourhood embedding (t-SNE) analy-
sis to obtain a two-dimensional map of the brain regions. 
Brain regions are placed nearby in this map if they have 
a similar expression profile across all genes. This map 
was then used to manually define nine groups of brain 
regions, as is shown in figure  2 of [21]. The regions of 
the ADNI data were manually linked to the nine region 
groups, as shown in Additional file 1: Table S1. The ana-
tomical atlas used for the Allen Atlas is hierarchical: it 
has a tree-like structure with large regions containing 
smaller regions. Table 1 shows a higher-level description 
of the regions in the nine region groups. In most cases 
the Allen Atlas regions were more general (larger) than 
the FreeSurfer regions of the ADNI data. Out of the 112 
regions, 105 regions were linked to a region group, while 
the other 7 regions did not have corresponding samples 
in the Allen Atlas data and were therefore left out.
3  Results
3.1  Simulation
To evaluate the performance of our model, the SEM was 
fitted to each of the simulated data sets. We considered 
two measures for model comparison. First, we set out to 
assess the prediction of phenotypes from the latent vari-
ables, with a logistic regression. In each of the 100 sim-
ulated data sets, we estimated the latent variable scores 
and used only those to predict the phenotype. For each 
of these 100 models, we obtained an Akaike information 
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criterion (AIC) value. We compared our model to several 
logistic regression models that use only the simulated 
data, instead of the SEM estimated latent scores. The first 
alternative model uses only all the brain region measure-
ments, the second only all the SNP measurements, and 
the third a combination of all regions and SNP measure-
ments. As a fourth alternative model, we performed a 
PCA on the volume measurements and extracted the first 
five principal components. Figure 2 shows that, on aver-
age, our latent variables obtain a lower AIC than models 
using either all brain region data, all SNP data, or both. 
The model using the first five principal components of 
the brain region data is most similar to our model, and it 
only has a slightly higher AIC on average than our model.
The second measure for model comparison is the abil-
ity to retrieve the correct SNPs. In each of our simulation 
data sets, two of the five latent variables have an effect on 
the phenotype (disease status). All SNPs that affect either 
of these two latent variables effectively impact the phe-
notype. We consider those SNPs to be the SNPs with a 
true effect. We now consider how these SNPs are ranked 
for importance in our SEM analysis, and two alternative 
approaches. From our SEM fit, we extracted the robust 
SNP p values for predicting the latent variables (so the p 
values for the estimates in A ). These give an impression 
of the importance of a SNP in predicting the latent varia-
bles. In addition, we used the latents’ logistic regression p 
values for the phenotype. These show the importance of 
a latent variable in predicting the phenotype. As a result, 
the path from a SNP to the phenotype contains two p val-
ues per latent variable: one for the latent variable predic-
tion and one for the phenotype prediction.
We considered combining these p values in two 
ways: (1) for each SNP we took the maximum p value 
of the two per latent variable and then the minimum p 
value over the five latent variables; or (2) for each SNP 
we used Fisher’s method [26] to combine the two p val-
ues per latent variable ( −2
∑
log(pi) ) and then took the 
minimum p value over the five latent variables. Note that 
Fisher’s method is meant for p values testing the same 
null hypothesis, which is not the case here. Both meth-
ods yield a score (p value) for SNP importance. We var-
ied a threshold for this score from 0 to 1 and compared 
the set of SNPs with values below this threshold to the 
set of SNPs with a known true effect. In this way, we con-
structed a receiver operating characteristic curve for SNP 
retrieval and calculated the corresponding area under the 
curve (AUC).
We compared the performance of our methodology to 
a straightforward modelling approach: a logistic regres-
sion to predict the disease status phenotype from the 
SNPs. This was performed both in a univariate way (as 
in a GWAS) and in a multivariate way. Figure  3 shows 
the performance of our SEM-based methods, using the 
maximum p value per SNP–latent combination (SEM 
max) or using Fisher’s method (SEM Fisher), and of the 
GWAS-like approaches. The SEM max method has the 
highest average AUC, indicating that it is best able to 
rank the SNPs on their importance for the phenotype. 
Table 1 The nine region groups (corresponding 
to the latent variables), with the brain regions they contain
These are higher-level labels of the Allen Atlas [12]. A full subdivision of the 
ADNI FreeSurfer regions into these region groups is provided in Additional file 1: 
Table S1
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Fig. 2 Simulation AIC model fit. The logistic regression models use 
either the SEM estimated latent variable scores (fitted latents), the first 
five principal components of the brain region data (5 PCs regions), all 
brain region data, all SNP and brain region data, or all SNP data
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Note that the SEM Fisher method has the disadvantage 
that either a strong SNP-to-latent or a strong latent-to-
phenotype effect can lead to a low combined p value, 
regardless of the other value. The observed difference 
between the univariate and multivariate approach is very 
small, which is to be expected since the simulated SNP 
values are independent.
To test the robustness of our model, we also compared 
the models for a range of alternative simulation settings. 
Additional file 2: Fig. S1 shows the results of these simu-
lations. The amount of noise on the latent variables has 
a similar impact on all compared methods. With a large 
amount of noise on the brain region measurements, the 
prediction of phenotypes remains best with our model, 
but the identification of SNPs is better with methods 
that do not make use of these region volume data. The 
number of SNPs with a nonzero effect on the latent vari-
able has little impact on the simulation results. Misspeci-
fication of the region groups, on the other hand, has a 
negative impact specifically on the performance of our 
method. This shows that our approach is somewhat sen-
sitive to the specification of brain region groups.
3.2  ADNI application
We apply our methodology to the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) data [9]. We selected 35 
SNPs and 105 brain region volumes for 746 individuals. 
The brain regions were divided into nine region groups 
based on the gene expression patterns of matching brain 
areas in the healthy human brain [12, 21]. Each of the 
nine brain region groups has one corresponding latent 
variable, and each latent variable has a unique set of brain 
region measurements attached to it. Additional file  3: 
Fig. S2 shows the volume loadings for each of the latent 
variables. Since the first loading for each latent variable 
is set to 1, the latent variables will have the same direc-
tion of effect as this variable. All but two of the region 
volumes have a positive loading. Two regions in the sub-
cortical group 2 (SubCort2) are negatively correlated to 
the latent variable scores, reflecting a more heterogene-
ous signal in this group.
Figure 4 shows the association between the nine latent 
variables and the selected SNPs. Only those SNPs are 
shown that have a nominally significant ( p < 0.05 ) asso-
ciation with at least one of the latent variables. After cor-
rection for multiple testing, the only significant effect is 
that for rs429358, located in APOE, on the hippocampal 
region group (Bonferroni-corrected p = 2.28× 10−4 ). In 
the validation set, here used as a replicate, this effect was 
again significant (Bonferroni-corrected p = 8.66× 10−3 ). 
None of the other associations are significant after multi-
ple testing correction. This APOE allele is known to be 
associated with a decrease in the hippocampal volume, 
both in individuals with mild cognitive impairment [27] 
and in Alzheimer’s disease [28].
The latent variables reflect differences in brain region 
volumes across the ADNI data set. To test whether these 
differences in brain region volumes are related to the dis-
ease phenotype, we compared the latent variable scores 
between the CN, LMCI, and AD individuals. Figure  5 
shows the distribution of latent variable scores for the 
validation set. To calculate these, we used the fitted SEM 
of the training data and used its parameter estimates to 
calculate latent variable scores for the validation data. For 
three region groups the latent variable scores were signif-
icantly lower in LMCI than in controls, and even lower in 
AD. These regions are the cerebral cortex, the hippocam-
pal formation, and the amygdala. This reflects significant 
shrinkage in these areas during Alzheimer’s disease pro-
gression. The region group of sulci and spaces (SulcSpac) 
has a latent variable that significantly increases in LMCI 
and AD. The significant association between the SNP 
rs429358 and the latent variable scores for hippocampus 
reflects the importance of APOE for Alzheimer’s disease.
4  Conclusion
We have proposed the use of a maximum likelihood 
structural equation model for combining SNP data and 
structural brain area measurements. The model makes 
use of external gene expression data, to define groups 
of brain regions that may respond similarly to genetic 















Fig. 3 Simulation AUC for SNP selection. Shown are the results for 
two methods of p value integration for our model (SEM max and 
SEM Fisher), for multivariate logistic regression and univariate logistic 
regression. A high AUC means that the method correctly ranks the 
importance of the SNPs for the phenotype (disease state)
Page 8 of 10Huisman et al. Brain Inf.            (2018) 5:13 
variation. For each of these region groups, we define a 
latent variable, which captures the relationship between 
the regions in a group and genetic variation. We have 
applied the model to a simulated data set, to show it can 
capture disease-relevant variation and identify causal 
SNPs. In addition, we have applied the model to the 
ADNI data set, containing Alzheimer’s patients, indi-
viduals with late mild cognitive impairment, and cogni-
tive healthy controls. One SNP, linked to APOE, shows 
a reproducible significant relationship to the latent vari-
able that captures hippocampal volume change. This 
latent variable, and the ones representing  the cerebral 
cortex, amygdala, and sulci and spaces, also significantly 
associate with the disease diagnosis. This shows that our 
approach can be used to integrate several data types and 
yield interpretable results.
The fitting process of the structural equation model 
has relatively high computational cost. It is truly multi-
variate, which makes it infeasible at the moment to per-
form genome-wide analysis. It does have advantages 
for incorporating a large number of variables, since it 

















Fig. 4 Association between SNPs and latent variable scores, as found by the robust maximum likelihood fit of the SEM. All nominally significant 
associations ( p < 0.05 ) are coloured by their robust z-statistic values [23]. The linked genes [25] are shown in brackets. a The results for the training 
set. After Bonferroni correction for the 315 tests, only the effect of rs429358 (APOE) on the hippocampus region group remains significant. b The 

















































































Fig. 5 Association between the validation latent variable scores and diagnosis. Diagnosis is cognitive normal (CN), late mild cognitive impairment 
(LMCI), or Alzheimer’s disease (AD). Nominally significant differences (ANOVA p < 0.05 ) are indicated with asterisks. The cerebral cortex (CrCortex), 
hippocampus (Hippocam), and amygdala (Amygdala) latent volume variables are lowered with disease progression, while the latent variable score 
for sulci and spaces (SulcSpac) is increased
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the parameter estimates [23]. With a constraint on the 
sum of squared weights, one could for instance imple-
ment a ridge regression. In addition, the model allows for 
the inclusion of additional data. This can be done either 
in the specification of the model structure, as we have 
done for the region groups, or by adding observed vari-
ables to the model. In our model, we chose to group brain 
regions based on the similarity of their expression pro-
files in the healthy brain. An interesting extension to the 
model would be to incorporate a layer of latent variables 
to reflect a grouping of the SNPs. These groups could also 
be based on the similarity of the brain-wide expression 
patterns of the associated genes.
These results show that maximum likelihood SEM is 
a versatile approach for data integration, which can be 
used to elucidate the relationships between genetic varia-
tion, structural brain phenotypes, and brain disease.
Additional files
Additional file 1: Table S1. All brain regions used in the ADNI section, 
with their region group code, manually annotated ABA region, ADNI code, 
and ADNI description. Region group codes: CrCortex = cerebral cortex; 
Hippocam = hippocampal formation; Amygdala = amygdala; Striatum = 
striatum; DorsThal = dorsal thalamus; SubCort1 = sub-cortical regions 1; 
SubCort2 = sub-cortical regions 2; ClCortex = cerebellar cortex; SulcSpac 
= sulci and spaces.
Additional file 2: Fig. S1. Simulations to test model robustness. The plots 
show a comparison of our model (red) to alternative approaches with 
varying simulation parameters. We simulated a range of noise on latent 
variables, noise on volumes, number of SNPs, and number of misspecified 
latent to volume links.
Additional file 3: Fig. S2. Weights (loadings) from the latent variables 
to the region measurements. The rows correspond to latent variables 
(region groups), and the columns to brain regions. Each first loading per 
region group was set to 1, for model identifiability. The loadings show 
the strength of the relationship between each latent variable and the 
thickness/volume of its corresponding brain regions. See Additional file 1: 
Table S1 for the meaning of the region codes.
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